Open AccessHepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)
Author(s) -
Johannes Wiegand,
Peter Buggisch,
Stefan Mauss,
Klaus Boeker,
Hartwig Klinker,
Tobias Müller,
Rainer Günther,
Yvonne Serfert,
Michael P. Manns,
Stefan Zeuzem,
Thomas Berg,
Holger Hinrichsen,
German Hepatitis C-Registry
Publication year - 2019
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 102
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/meg.0000000000001426
Subject(s) - medicine , tolerability , sofosbuvir , renal function , ribavirin , adverse effect , hepatitis c , kidney disease , ritonavir , gastroenterology , hepatitis c virus , urology , viral load , virology , virus , antiretroviral therapy
Direct-acting antiviral agents (DAAs) have revolutionized treatment of chronic hepatitis C in patients with normal glomerular filtration rate (GFR). However, patients with impaired kidney function have been excluded from several clinical trials. We, therefore, investigated the use, effectiveness, and tolerability of DAAs in patients with GFR less than 30 ml/min in the real-world setting.